Curaleaf International Achieves EU Certification for Innovative Cannabis Device
Curaleaf International, in collaboration with Jupiter Research LLC, has achieved a significant milestone by securing EU medical device certification under Regulation (EU) 2017/745. This marks the approval of the first handheld liquid inhalation device specifically designed for the precise administration of medical cannabis. Branded as a Class IIa medical device, it aligns with the stringent regulatory standards set in Europe, paving the way for a new era in targeted cannabis treatment.
The device, distinguished by its magnetic snap-in cartridge and rechargeable power supply, has demonstrated compliance through a detailed technical file and an EU Declaration of Conformity. Both documents received favorable evaluation from an EU Notified Body, affirming the device’s quality, safety, and clinical efficacy. This certification empowers healthcare professionals to recommend the device across Europe, Canada, Australasia, and the UK, highlighting its potential in expanding medical cannabis application on a global scale.
Pioneering Innovation in Medical Cannabis
Boris Jordan, Chairman and CEO of Curaleaf, emphasized the broader implications of achieving EU certification, stating it signifies the integration of medical cannabis into mainstream global healthcare. Jordan expressed pride in introducing a device that meets the highest safety and quality standards, offering an accurate and discreet treatment option for patients and healthcare providers across multiple regions.
TILT’s CEO, Tim Conder, reflected on the milestone as the latest chapter in their ongoing partnership with Curaleaf International. He highlighted how this collaboration has resulted in industry-leading, user-friendly healthcare solutions. The EU certification serves as validation of the robust engineering and research capabilities at Jupiter Research, setting a new benchmark for innovation within the cannabis sector.
With this groundbreaking development, Curaleaf and Jupiter Research are poised to redefine medical cannabis delivery, reinforcing their commitment to leading innovation, enhancing patient outcomes, and broadening market accessibility.
#CannabisInnovation #MedicalCannabis #EUCertification #CannabisNews #CannabisIndustry